sumatriptan ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
serotonin (5-HT1) receptor agonists, sumatriptan derivatives 2543 103628-46-2

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • GR43175
  • GR 43175
  • sumatriptan
  • sumatriptan succinate
A serotonin agonist that acts selectively at 5HT1 receptors. It is used in the treatment of MIGRAINE DISORDERS.
  • Molecular weight: 295.40
  • Formula: C14H21N3O2S
  • CLOGP: 0.74
  • LIPINSKI: 0
  • HAC: 5
  • HDO: 2
  • TPSA: 65.20
  • ALOGS: -3.37
  • ROTB: 5

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
20 mg N
50 mg O
6 mg P
25 mg R

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 21.40 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 22 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.68 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 14 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 1.70 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 19 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.83 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 1.70 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Dec. 28, 1992 FDA GLAXOSMITHKLINE

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Product physical issue 4103.62 11.46 911 45263 3671 56242222
Migraine 1094.57 11.46 751 45423 86046 56159847
Product dose omission issue 1052.84 11.46 1051 45123 203702 56042191
Application site erythema 566.64 11.46 192 45982 4408 56241485
Product quality issue 507.34 11.46 319 45855 31417 56214476
Application site burn 379.94 11.46 95 46079 692 56245201
Device deployment issue 334.31 11.46 122 46052 3502 56242391
Application site pain 328.61 11.46 123 46051 3797 56242096
Device malfunction 327.09 11.46 189 45985 15947 56229946
Application site discolouration 266.63 11.46 71 46103 681 56245212
Device issue 256.73 11.46 179 45995 20927 56224966
Application site paraesthesia 193.47 11.46 36 46138 39 56245854
Headache 146.92 11.46 869 45305 558175 55687718
Rheumatoid arthritis 145.60 11.46 66 46108 382538 55863355
Accidental exposure to product 145.51 11.46 137 46037 24510 56221383
Application site urticaria 138.40 11.46 34 46140 228 56245665
Application site rash 132.97 11.46 56 46118 2367 56243526
Medication overuse headache 125.51 11.46 39 46135 672 56245221
Application site irritation 124.61 11.46 48 46126 1604 56244289
Colitis ischaemic 117.21 11.46 83 46091 9937 56235956
Application site warmth 115.17 11.46 27 46147 144 56245749
Application site pruritus 111.53 11.46 57 46117 3762 56242131
Arteriospasm coronary 96.66 11.46 51 46123 3596 56242297
Anxiety 95.16 11.46 361 45813 192811 56053082
Glossodynia 92.52 11.46 9 46165 152449 56093444
Needle issue 89.96 11.46 67 46107 8671 56237222
Death 89.43 11.46 89 46085 341337 55904556
Injection site pain 86.39 11.46 251 45923 116867 56129026
Application site scar 82.89 11.46 22 46152 208 56245685
Systemic lupus erythematosus 82.11 11.46 23 46151 180055 56065838
Application site vesicles 79.79 11.46 33 46141 1332 56244561
Paraesthesia 77.13 11.46 259 45915 130255 56115638
Arthropathy 76.91 11.46 34 46140 200241 56045652
Injection site haemorrhage 75.29 11.46 92 46082 22109 56223784
Throat tightness 73.00 11.46 91 46083 22316 56223577
Wound 72.76 11.46 13 46161 138791 56107102
Application site swelling 71.66 11.46 24 46150 530 56245363
Contraindicated product administered 70.93 11.46 32 46142 186254 56059639
Product substitution issue 69.17 11.46 72 46102 14527 56231366
Infusion related reaction 69.10 11.46 43 46131 208888 56037005
Reversible cerebral vasoconstriction syndrome 68.03 11.46 35 46139 2342 56243551
IIIrd nerve paresis 67.60 11.46 17 46157 127 56245766
Wrong technique in product usage process 67.36 11.46 148 46026 58020 56187873
Device power source issue 65.26 11.46 22 46152 496 56245397
Muscle twitching 64.53 11.46 73 46101 16169 56229724
Treatment failure 63.73 11.46 30 46144 170362 56075531
Drug ineffective 63.69 11.46 1081 45093 917908 55327985
Product complaint 63.03 11.46 62 46112 11698 56234195
Depression 62.64 11.46 303 45871 179814 56066079
Cerebral vasoconstriction 62.02 11.46 26 46148 1086 56244807
Acute kidney injury 61.57 11.46 64 46110 240699 56005194
Serotonin syndrome 59.69 11.46 90 46084 26400 56219493
Coronary artery dissection 56.56 11.46 22 46152 755 56245138
Application site exfoliation 56.28 11.46 18 46156 342 56245551
Anaemia 55.94 11.46 83 46091 267428 55978465
Product leakage 55.25 11.46 21 46153 676 56245217
Endometriosis 55.11 11.46 39 46135 4663 56241230
Application site dryness 55.05 11.46 15 46159 158 56245735
Concussion 54.81 11.46 49 46125 8197 56237696
Chest discomfort 53.86 11.46 191 45983 98666 56147227
Dizziness 53.78 11.46 507 45667 375633 55870260
Cholecystitis chronic 53.38 11.46 52 46122 9696 56236197
Abdominal discomfort 52.37 11.46 92 46082 277182 55968711
Joint swelling 52.20 11.46 99 46075 289701 55956192
Application site reaction 51.98 11.46 20 46154 666 56245227
Lower respiratory tract infection 51.67 11.46 15 46159 114779 56131114
Pituitary tumour benign 51.20 11.46 27 46147 1901 56243992
Post-traumatic neck syndrome 50.55 11.46 27 46147 1951 56243942
Injection site bruising 50.36 11.46 103 46071 38418 56207475
Emotional distress 49.29 11.46 88 46086 29675 56216218
Application site scab 48.98 11.46 14 46160 178 56245715
Somnambulism 47.90 11.46 37 46137 5055 56240838
Renal infarct 47.37 11.46 23 46151 1359 56244534
Hostility 46.81 11.46 25 46149 1806 56244087
Device leakage 46.63 11.46 40 46134 6335 56239558
Drug specific antibody 46.53 11.46 26 46148 2054 56243839
Alopecia 46.34 11.46 108 46066 293350 55952543
Swelling 45.77 11.46 79 46095 239692 56006201
Incorrect dose administered by device 45.65 11.46 32 46142 3768 56242125
Libido increased 45.47 11.46 22 46152 1290 56244603
Febrile neutropenia 45.34 11.46 15 46159 105530 56140363
Cardiac failure 44.53 11.46 7 46167 82086 56163807
Soft tissue injury 44.19 11.46 23 46151 1576 56244317
Neutropenia 42.76 11.46 40 46134 158127 56087766
Incorrect route of product administration 41.84 11.46 68 46106 21261 56224632
Expired product administered 40.67 11.46 35 46139 5567 56240326
Off label use 40.36 11.46 279 45895 555901 55689992
Hepatic enzyme increased 40.03 11.46 49 46125 171335 56074558
Application site inflammation 39.55 11.46 14 46160 367 56245526
Nightmare 39.09 11.46 58 46116 16768 56229125
Disease progression 38.57 11.46 19 46155 105154 56140739
Application site bruise 38.57 11.46 13 46161 293 56245600
Tension headache 38.54 11.46 26 46148 2877 56243016
Sternal fracture 38.44 11.46 23 46151 2067 56243826
Suicidal ideation 38.05 11.46 119 46055 57623 56188270
Synovitis 37.79 11.46 46 46128 161259 56084634
Hot flush 37.20 11.46 103 46071 46623 56199270
Feeling abnormal 36.93 11.46 211 45963 133391 56112502
Nausea 36.57 11.46 851 45323 763327 55482566
Angle closure glaucoma 36.05 11.46 22 46152 2049 56243844
Clonus 35.94 11.46 29 46145 4220 56241673
Hypotension 35.05 11.46 98 46076 250410 55995483
Peripheral swelling 34.98 11.46 89 46085 234637 56011256
Infection 34.63 11.46 70 46104 200136 56045757
Secondary adrenocortical insufficiency 34.20 11.46 18 46156 1262 56244631
Pre-existing condition improved 34.17 11.46 36 46138 7362 56238531
Product use issue 33.95 11.46 63 46111 185978 56059915
Atrial fibrillation 33.83 11.46 24 46150 108873 56137020
Pneumonia 33.70 11.46 196 45978 406902 55838991
Hypoaesthesia 33.11 11.46 214 45960 141277 56104616
General physical health deterioration 32.44 11.46 56 46118 169954 56075939
Dysgeusia 32.38 11.46 90 46084 40825 56205068
Muscle tightness 32.12 11.46 42 46132 10794 56235099
Renal impairment 32.08 11.46 13 46161 80700 56165193
Therapeutic response unexpected 31.63 11.46 53 46121 16991 56228902
Impaired healing 31.37 11.46 16 46158 86825 56159068
Chest pain 31.24 11.46 264 45910 189533 56056360
Pancytopenia 31.08 11.46 17 46157 88698 56157195
Haemoglobin decreased 30.63 11.46 39 46135 134098 56111795
Diarrhoea 29.84 11.46 358 45816 638149 55607744
Hyponatraemia 28.59 11.46 25 46149 102114 56143779
Interstitial lung disease 28.50 11.46 6 46168 57057 56188836
Device defective 28.48 11.46 17 46157 1521 56244372
Hyperkalaemia 28.36 11.46 4 46170 50861 56195032
Application site discomfort 28.18 11.46 11 46163 381 56245512
Drug-disease interaction 28.13 11.46 11 46163 383 56245510
Renal tubular acidosis 27.91 11.46 17 46157 1578 56244315
Application site erosion 27.80 11.46 9 46165 178 56245715
Stomatitis 27.71 11.46 35 46139 120775 56125118
Plasma cell myeloma 27.64 11.46 3 46171 46643 56199250
Platelet count decreased 27.47 11.46 28 46146 106355 56139538
Transient global amnesia 27.29 11.46 12 46162 564 56245329
Hyperprolactinaemia 26.83 11.46 23 46151 3638 56242255
Pharyngeal swelling 26.64 11.46 27 46147 5279 56240614
Cluster headache 26.31 11.46 12 46162 615 56245278
Poor quality sleep 26.25 11.46 50 46124 17705 56228188
Photophobia 25.99 11.46 47 46127 16003 56229890
Vasospasm 25.97 11.46 12 46162 634 56245259
Malignant neoplasm progression 25.93 11.46 14 46160 73573 56172320
Migraine without aura 25.77 11.46 10 46164 341 56245552
Rash 24.72 11.46 272 45902 492775 55753118
Palpitations 24.70 11.46 153 46021 99519 56146374
Somnolence 24.64 11.46 223 45951 163190 56082703
Gastrointestinal haemorrhage 24.57 11.46 16 46158 75935 56169958
Blood creatinine increased 24.48 11.46 18 46156 80173 56165720
Pleural effusion 23.82 11.46 21 46153 85459 56160434
Eyelid ptosis 23.71 11.46 28 46146 6491 56239402
Injection site laceration 23.68 11.46 7 46167 101 56245792
Drug hypersensitivity 23.51 11.46 336 45838 274869 55971024
Tremor 23.51 11.46 175 45999 120914 56124979
Narcolepsy 23.03 11.46 14 46160 1295 56244598
Middle insomnia 22.97 11.46 36 46138 10914 56234979
Oxygen saturation decreased 22.55 11.46 19 46155 79048 56166845
Sepsis 22.41 11.46 51 46123 139789 56106104
Application site papules 21.95 11.46 6 46168 64 56245829
Personality disorder 21.83 11.46 24 46150 5149 56240744
Vasoconstriction 21.67 11.46 10 46164 527 56245366
Hip arthroplasty 21.62 11.46 3 46171 38620 56207273
Vision blurred 21.61 11.46 129 46045 82814 56163079
Underdose 21.57 11.46 55 46119 23702 56222191
Irritability 21.38 11.46 63 46111 29525 56216368
Blood testosterone increased 20.88 11.46 7 46167 155 56245738
Septic shock 20.81 11.46 12 46162 60823 56185070
Post-traumatic stress disorder 20.81 11.46 22 46152 4516 56241377
Injection site injury 20.80 11.46 10 46164 578 56245315
Muscle spasms 20.47 11.46 187 45987 137184 56108709
Gastrooesophageal reflux disease 20.12 11.46 127 46047 83130 56162763
Dependence 19.86 11.46 15 46159 1982 56243911
Phonophobia 19.85 11.46 8 46166 302 56245591
Pyrexia 19.81 11.46 234 45940 418539 55827354
Neck pain 19.55 11.46 101 46073 61454 56184439
Migraine with aura 19.53 11.46 16 46158 2378 56243515
Cardiac failure congestive 19.51 11.46 26 46148 87694 56158199
Basilar migraine 19.47 11.46 5 46169 41 56245852
Product adhesion issue 19.27 11.46 21 46153 4462 56241431
Neonatal respiratory distress 19.02 11.46 8 46166 337 56245556
Large intestinal ulcer haemorrhage 18.96 11.46 6 46168 110 56245783
Renal failure 18.78 11.46 39 46135 110461 56135432
Biliary dyskinesia 18.58 11.46 16 46158 2547 56243346
Spleen congestion 18.57 11.46 6 46168 118 56245775
Sunburn 18.55 11.46 16 46158 2552 56243341
Cerebral venous thrombosis 18.21 11.46 14 46160 1899 56243994
Paraesthesia oral 18.13 11.46 38 46136 14411 56231482
Red blood cell sedimentation rate increased 17.98 11.46 4 46170 36619 56209274
Thrombocytopenia 17.79 11.46 55 46119 136169 56109724
Depressive symptom 17.74 11.46 18 46156 3523 56242370
Osteonecrosis of jaw 17.74 11.46 3 46171 33355 56212538
Incorrect product administration duration 17.70 11.46 31 46143 10295 56235598
Device use error 17.51 11.46 22 46152 5434 56240459
Decreased appetite 17.33 11.46 107 46067 219124 56026769
Complement factor C4 decreased 17.32 11.46 7 46167 266 56245627
Discomfort 17.29 11.46 59 46115 141702 56104191
Multiple organ dysfunction syndrome 17.23 11.46 11 46163 52759 56193134
Blister 17.21 11.46 40 46134 108847 56137046
Hyperhidrosis 17.15 11.46 134 46040 93954 56151939
Lactic acidosis 17.08 11.46 4 46170 35342 56210551
Complement factor C3 decreased 16.82 11.46 7 46167 287 56245606
Memory impairment 16.74 11.46 125 46049 86432 56159461
Cough 16.59 11.46 135 46039 259826 55986067
Seizure 16.50 11.46 166 46008 124953 56120940
Application site dermatitis 16.41 11.46 6 46168 173 56245720
Subclavian artery thrombosis 16.41 11.46 6 46168 173 56245720
Meningoradiculitis 16.38 11.46 5 46169 81 56245812
Sleep talking 16.33 11.46 10 46164 937 56244956
Drug dependence 16.30 11.46 48 46126 22485 56223408
Knee arthroplasty 16.21 11.46 8 46166 44251 56201642
International normalised ratio increased 16.07 11.46 8 46166 44033 56201860
Superior sagittal sinus thrombosis 16.03 11.46 9 46165 718 56245175
Bipolar disorder 16.01 11.46 25 46149 7555 56238338
Major depression 16.00 11.46 25 46149 7559 56238334
Hyperacusis 15.97 11.46 13 46161 1915 56243978
Transverse sinus thrombosis 15.81 11.46 8 46166 517 56245376
Gastrointestinal disorder 15.80 11.46 44 46130 112658 56133235
Maternal exposure during pregnancy 15.78 11.46 91 46083 189462 56056431
Injury 15.53 11.46 93 46081 59758 56186135
Burning sensation 15.53 11.46 80 46094 48616 56197277
Multiple sclerosis 15.36 11.46 54 46120 27748 56218145
Hyperreflexia 15.02 11.46 20 46154 5230 56240663
Injury associated with device 15.01 11.46 16 46158 3317 56242576
Lichen planus 14.78 11.46 13 46161 2129 56243764
Cerebral venous sinus thrombosis 14.75 11.46 12 46162 1766 56244127
Liver injury 14.68 11.46 8 46166 41840 56204053
Peripheral nerve injury 14.59 11.46 7 46167 403 56245490
Gallbladder disorder 14.58 11.46 39 46135 17295 56228598
Rash maculo-papular 14.51 11.46 3 46171 28904 56216989
Multiple sclerosis relapse 14.48 11.46 74 46100 44829 56201064
Nipple pain 14.39 11.46 6 46168 247 56245646
Drug effect less than expected 14.32 11.46 9 46165 883 56245010
Trismus 14.15 11.46 16 46158 3542 56242351
Bone marrow failure 14.07 11.46 3 46171 28283 56217610
Teratogenicity 14.04 11.46 6 46168 263 56245630
Pancreatic failure 14.02 11.46 9 46165 916 56244977
Withdrawal syndrome 14.00 11.46 40 46134 18422 56227471
Potassium wasting nephropathy 13.91 11.46 4 46170 52 56245841
Inflammation 13.86 11.46 22 46152 69049 56176844
Ischaemic cerebral infarction 13.83 11.46 10 46164 1236 56244657
Burns third degree 13.75 11.46 6 46168 277 56245616
Sensory disturbance 13.49 11.46 31 46143 12512 56233381
Gallbladder injury 13.45 11.46 10 46164 1290 56244603
Therapeutic response shortened 13.35 11.46 26 46148 9360 56236533
Slow speech 13.27 11.46 10 46164 1317 56244576
Pneumonia aspiration 13.24 11.46 5 46169 32406 56213487
Post viral fatigue syndrome 13.20 11.46 6 46168 305 56245588
Premature delivery 13.20 11.46 3 46171 27057 56218836
Deep vein thrombosis 13.13 11.46 108 46066 76869 56169024
Cholestasis 13.09 11.46 3 46171 26910 56218983
Hepatic function abnormal 13.04 11.46 6 46168 34552 56211341
Neoplasm progression 12.97 11.46 5 46169 32011 56213882
Meningitis aseptic 12.96 11.46 17 46157 4382 56241511
Influenza like illness 12.90 11.46 90 46084 60898 56184995
Toxicity to various agents 12.82 11.46 120 46054 224444 56021449
Cardio-respiratory arrest 12.71 11.46 16 46158 55305 56190588
Granulocyte count increased 12.41 11.46 7 46167 563 56245330
Hepatotoxicity 12.40 11.46 5 46169 31148 56214745
Pharyngeal oedema 12.31 11.46 31 46143 13254 56232639
Nasal discomfort 12.22 11.46 16 46158 4116 56241777
Melaena 12.18 11.46 4 46170 28286 56217607
Alanine aminotransferase increased 12.09 11.46 38 46136 93624 56152269
Chemical burn 12.07 11.46 6 46168 373 56245520
Swollen tongue 11.98 11.46 53 46121 30271 56215622
Ovarian neoplasm 11.97 11.46 8 46166 872 56245021
Blood HIV RNA increased 11.95 11.46 7 46167 605 56245288
Product packaging quantity issue 11.81 11.46 9 46165 1205 56244688
Ill-defined disorder 11.80 11.46 24 46150 68519 56177374
Flushing 11.77 11.46 98 46076 70002 56175891
Therapeutic product effect decreased 11.74 11.46 86 46088 169366 56076527
Oedema 11.47 11.46 32 46142 81888 56164005

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Product physical issue 983.18 17.99 199 7278 2056 31687811
Migraine 288.91 17.99 113 7364 14067 31675800
Product dose omission issue 237.32 17.99 197 7280 105389 31584478
Product quality issue 123.61 17.99 65 7412 16046 31673821
Headache 98.63 17.99 164 7313 183488 31506379
Device deployment issue 95.73 17.99 18 7459 120 31689747
Arteriospasm coronary 69.39 17.99 26 7451 2865 31687002
Cluster headache 61.77 17.99 16 7461 514 31689353
Device malfunction 61.56 17.99 34 7443 9232 31680635
Device issue 56.00 17.99 31 7446 8453 31681414
Serotonin syndrome 50.36 17.99 39 7438 18734 31671133
Throat tightness 47.83 17.99 27 7450 7642 31682225
IIIrd nerve paresis 44.89 17.99 9 7468 87 31689780
Accidental exposure to product 42.48 17.99 29 7448 11466 31678401
Hyperhidrosis 37.06 17.99 61 7416 67332 31622535
Injection site pain 35.01 17.99 42 7435 34592 31655275
Application site pain 32.28 17.99 13 7464 1736 31688131
Medication overuse headache 31.38 17.99 7 7470 117 31689750
Myofascial pain syndrome 29.54 17.99 8 7469 306 31689561
Drug ineffective 27.55 17.99 173 7304 395400 31294467
Application site burn 27.48 17.99 7 7470 210 31689657
Acute kidney injury 27.48 17.99 16 7461 279698 31410169
Xanthelasma 27.20 17.99 6 7471 95 31689772
Gastrointestinal tract irritation 26.87 17.99 7 7470 230 31689637
Anophthalmos 26.64 17.99 4 7473 4 31689863
Needle issue 26.13 17.99 16 7461 5257 31684610
Congenital genital malformation male 25.02 17.99 4 7473 8 31689859
Facial pain 24.27 17.99 11 7466 1960 31687907
Burns second degree 23.90 17.99 7 7470 357 31689510
Foetal malnutrition 23.88 17.99 5 7472 61 31689806
Autonomic dysreflexia 23.31 17.99 5 7472 69 31689798
Electrocardiogram ST segment elevation 22.76 17.99 14 7463 4637 31685230
Foetal exposure during pregnancy 22.45 17.99 37 7440 40839 31649028
Death 21.96 17.99 32 7445 360537 31329330
Chest pain 21.96 17.99 69 7408 116888 31572979
Capillaritis 21.38 17.99 5 7472 104 31689763
Paraesthesia 20.98 17.99 43 7434 56028 31633839
Muscle tightness 20.56 17.99 13 7464 4516 31685351
Application site erythema 20.42 17.99 10 7467 2119 31687748
Craniosynostosis 19.85 17.99 6 7471 341 31689526
Aphasia 19.85 17.99 24 7453 19907 31669960
Irritable bowel syndrome 19.47 17.99 11 7466 3117 31686750
Tobacco abuse 18.91 17.99 6 7471 401 31689466
Chest discomfort 18.63 17.99 38 7439 49331 31640536
Anaemia 18.53 17.99 14 7463 213508 31476359
Injection site haemorrhage 18.32 17.99 16 7461 9069 31680798

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Product physical issue 1336.42 12.29 329 39877 3385 70884853
Migraine 1151.10 12.29 635 39571 71603 70816635
Application site erythema 407.88 12.29 138 40068 4623 70883615
Product dose omission issue 325.15 12.29 500 39706 216968 70671270
Application site burn 286.92 12.29 71 40135 745 70887493
Application site pain 238.87 12.29 91 40115 4311 70883927
Product quality issue 233.56 12.29 169 40037 30392 70857846
Headache 217.06 12.29 771 39435 579634 70308604
Application site discolouration 195.39 12.29 51 40155 673 70887565
Application site paraesthesia 182.68 12.29 32 40174 37 70888201
Device malfunction 182.14 12.29 121 40085 18963 70869275
Arteriospasm coronary 150.97 12.29 72 40134 5952 70882286
Accidental exposure to product 144.68 12.29 123 40083 27928 70860310
Medication overuse headache 132.73 12.29 38 40168 721 70887517
IIIrd nerve paresis 118.60 12.29 26 40180 151 70888087
Throat tightness 117.48 12.29 104 40102 24918 70863320
Colitis ischaemic 112.15 12.29 80 40126 14057 70874181
Acute kidney injury 110.81 12.29 66 40140 474558 70413680
Anxiety 104.56 12.29 318 39888 220012 70668226
Application site pruritus 102.49 12.29 47 40159 3554 70884684
Application site warmth 101.09 12.29 23 40183 162 70888076
Application site irritation 100.76 12.29 37 40169 1580 70886658
Device deployment issue 98.68 12.29 43 40163 2881 70885357
Paraesthesia 95.90 12.29 237 39969 145300 70742938
Death 92.27 12.29 92 40114 509969 70378269
Application site urticaria 89.67 12.29 22 40184 222 70888016
Application site rash 89.48 12.29 36 40170 1973 70886265
Serotonin syndrome 85.10 12.29 112 40094 42002 70846236
Reversible cerebral vasoconstriction syndrome 82.60 12.29 37 40169 2648 70885590
Wrong technique in product usage process 79.50 12.29 141 40065 68557 70819681
Device issue 78.89 12.29 82 40124 23943 70864295
Anaemia 73.78 12.29 72 40134 403351 70484887
Endometriosis 73.02 12.29 36 40170 3200 70885038
Cluster headache 72.14 12.29 25 40181 900 70887338
Application site swelling 71.37 12.29 23 40183 659 70887579
Cerebral vasoconstriction 70.18 12.29 27 40179 1313 70886925
Application site scar 68.89 12.29 17 40189 176 70888062
Dizziness 68.69 12.29 474 39732 463667 70424571
Depression 66.88 12.29 256 39950 198718 70689520
Muscle twitching 65.69 12.29 68 40138 19759 70868479
Chest discomfort 65.10 12.29 186 40020 124195 70764043
Drug ineffective 60.59 12.29 804 39402 938948 69949290
Cardiac failure 59.79 12.29 6 40200 143535 70744703
Emotional distress 58.89 12.29 88 40118 37100 70851138
Injection site pain 58.77 12.29 173 40033 117446 70770792
Pituitary tumour benign 57.19 12.29 28 40178 2451 70885787
Rheumatoid arthritis 56.97 12.29 49 40157 291756 70596482
Post-traumatic neck syndrome 56.93 12.29 26 40180 1947 70886291
Application site vesicles 56.32 12.29 23 40183 1310 70886928
Incorrect route of product administration 55.92 12.29 72 40134 26420 70861818
Hot flush 53.82 12.29 99 40107 49485 70838753
Concussion 53.74 12.29 42 40164 8467 70879771
Febrile neutropenia 52.59 12.29 25 40181 204293 70683945
Cholecystitis chronic 52.23 12.29 43 40163 9333 70878905
Coronary artery dissection 51.76 12.29 20 40186 984 70887254
Hypoaesthesia 50.97 12.29 197 40009 153542 70734696
Soft tissue injury 50.65 12.29 23 40183 1699 70886539
Chest pain 50.58 12.29 278 39928 250982 70637256
Pneumonia 50.14 12.29 172 40034 596060 70292178
Nausea 49.94 12.29 717 39489 851371 70036867
Drug specific antibody 49.75 12.29 25 40181 2314 70885924
Hostility 47.67 12.29 24 40182 2231 70886007
Muscle tightness 47.61 12.29 45 40161 11717 70876521
Injection site haemorrhage 47.15 12.29 65 40141 25462 70862776
Neutropenia 46.84 12.29 46 40160 257110 70631128
Libido increased 45.80 12.29 22 40184 1847 70886391
Sepsis 45.40 12.29 43 40163 244502 70643736
Tension headache 45.05 12.29 27 40179 3534 70884704
Renal infarct 45.00 12.29 24 40182 2513 70885725
Application site exfoliation 44.80 12.29 14 40192 362 70887876
Application site dryness 44.67 12.29 12 40194 178 70888060
Sternal fracture 43.85 12.29 23 40183 2328 70885910
Disease progression 42.14 12.29 18 40188 156654 70731584
Product substitution issue 41.74 12.29 52 40154 18461 70869777
Renal failure 41.67 12.29 28 40178 189042 70699196
Infusion related reaction 41.24 12.29 31 40175 197503 70690735
Device power source issue 40.92 12.29 16 40190 813 70887425
Hyperkalaemia 40.60 12.29 6 40200 106585 70781653
Interstitial lung disease 39.63 12.29 6 40200 104679 70783559
Renal impairment 39.58 12.29 16 40190 143921 70744317
Hypotension 39.38 12.29 109 40097 404272 70483966
Injection site bruising 38.86 12.29 74 40132 37958 70850280
Pancytopenia 38.10 12.29 19 40187 151088 70737150
Treatment failure 38.07 12.29 17 40189 144125 70744113
Angle closure glaucoma 37.59 12.29 22 40184 2757 70885481
Platelet count decreased 37.16 12.29 28 40178 178194 70710044
Pericarditis 36.72 12.29 3 40203 84702 70803536
Hyponatraemia 36.23 12.29 23 40183 160064 70728174
Feeling abnormal 36.01 12.29 168 40038 142151 70746087
Clonus 35.45 12.29 29 40177 6239 70881999
Multiple organ dysfunction syndrome 35.25 12.29 9 40197 108506 70779732
Vision blurred 35.04 12.29 126 40080 94858 70793380
Thrombocytopenia 34.78 12.29 51 40155 239059 70649179
Atrial fibrillation 34.69 12.29 32 40174 184316 70703922
Application site inflammation 34.09 12.29 12 40194 453 70887785
Suicidal ideation 33.45 12.29 101 40105 69495 70818743
Glossodynia 32.64 12.29 5 40201 86482 70801756
Photophobia 32.23 12.29 46 40160 18604 70869634
Palpitations 31.98 12.29 136 40070 110617 70777621
Septic shock 31.65 12.29 12 40194 112246 70775992
Lower respiratory tract infection 31.49 12.29 12 40194 111901 70776337
Expired product administered 30.78 12.29 27 40179 6386 70881852
Drug hypersensitivity 30.78 12.29 254 39952 262205 70626033
Plasma cell myeloma 30.63 12.29 3 40203 73198 70815040
Wound 30.55 12.29 9 40197 98723 70789515
Nightmare 30.28 12.29 49 40157 22107 70866131
Application site scab 30.09 12.29 9 40197 200 70888038
Gastrointestinal haemorrhage 29.40 12.29 21 40185 137387 70750851
Blood creatinine increased 29.13 12.29 23 40183 142978 70745260
Injury 28.86 12.29 92 40114 65153 70823085
Pleural effusion 28.83 12.29 20 40186 132844 70755394
Pharyngeal swelling 28.66 12.29 26 40180 6427 70881811
Application site bruise 28.36 12.29 9 40197 245 70887993
Hyperprolactinaemia 28.34 12.29 22 40184 4391 70883847
Secondary adrenocortical insufficiency 28.23 12.29 18 40188 2629 70885609
Malignant neoplasm progression 28.23 12.29 17 40189 121722 70766516
Hyperhidrosis 28.07 12.29 148 40058 131438 70756800
Hepatic function abnormal 27.90 12.29 3 40203 67993 70820245
Haemoglobin decreased 27.69 12.29 46 40160 205113 70683125
Subclavian artery thrombosis 27.64 12.29 6 40200 33 70888205
Transient global amnesia 26.93 12.29 12 40194 848 70887390
Pyrexia 26.78 12.29 218 39988 606734 70281504
Product adhesion issue 26.51 12.29 17 40189 2507 70885731
Off label use 26.31 12.29 282 39924 742778 70145460
Personality disorder 25.91 12.29 23 40183 5525 70882713
Application site reaction 25.60 12.29 11 40195 712 70887526
Pain 25.58 12.29 499 39707 628317 70259921
Vasospasm 25.40 12.29 12 40194 971 70887267
Poor quality sleep 25.13 12.29 43 40163 20306 70867932
Electrocardiogram ST segment elevation 25.04 12.29 26 40180 7578 70880660
Application site discomfort 25.02 12.29 9 40197 362 70887876
Somnambulism 24.96 12.29 22 40184 5238 70883000
Dysgeusia 24.88 12.29 73 40133 49429 70838809
Product leakage 24.78 12.29 11 40195 770 70887468
Middle insomnia 24.78 12.29 35 40171 14018 70874220
Respiratory failure 24.52 12.29 36 40170 168699 70719539
Therapeutic response unexpected 24.48 12.29 40 40166 18191 70870047
Cerebral venous thrombosis 24.12 12.29 16 40190 2499 70885739
Incorrect dose administered by device 24.02 12.29 20 40186 4409 70883829
Device leakage 24.01 12.29 28 40178 9280 70878958
Memory impairment 23.89 12.29 110 40096 92531 70795707
Temperature intolerance 23.78 12.29 27 40179 8696 70879542
Cardiac failure congestive 23.77 12.29 25 40181 135432 70752806
Migraine without aura 23.75 12.29 8 40198 264 70887974
Muscle spasms 23.68 12.29 159 40047 153887 70734351
Infection 23.46 12.29 53 40153 210732 70677506
Vasoconstriction 23.18 12.29 10 40196 654 70887584
Phonophobia 22.76 12.29 9 40197 471 70887767
Product complaint 22.37 12.29 31 40175 12200 70876038
Gastrooesophageal reflux disease 22.06 12.29 106 40100 90733 70797505
Renal tubular acidosis 22.00 12.29 17 40189 3369 70884869
Insomnia 21.99 12.29 204 40002 217602 70670636
Drug dependence 21.67 12.29 58 40148 37263 70850975
Gallbladder disorder 21.31 12.29 37 40169 17675 70870563
Systemic lupus erythematosus 21.25 12.29 16 40190 101886 70786352
Tremor 21.20 12.29 156 40050 155468 70732770
Burning sensation 21.10 12.29 72 40134 52798 70835440
Neck pain 20.92 12.29 84 40122 66573 70821665
Head discomfort 20.87 12.29 31 40175 12992 70875246
Arthropathy 20.85 12.29 33 40173 150024 70738214
Myofascial pain syndrome 20.83 12.29 13 40193 1829 70886409
Irritability 20.79 12.29 58 40148 38167 70850071
General physical health deterioration 20.51 12.29 67 40139 235964 70652274
Pharyngeal oedema 20.49 12.29 34 40172 15662 70872576
Post-traumatic stress disorder 20.05 12.29 18 40188 4389 70883849
Pre-existing condition improved 19.98 12.29 19 40187 4983 70883255
Decreased appetite 19.85 12.29 97 40109 304683 70583555
Migraine with aura 19.83 12.29 14 40192 2418 70885820
Basilar migraine 19.67 12.29 5 40201 59 70888179
Paraesthesia oral 19.59 12.29 33 40173 15384 70872854
Application site papules 19.59 12.29 5 40201 60 70888178
Flushing 19.32 12.29 95 40111 82077 70806161
Burns second degree 19.31 12.29 10 40196 986 70887252
Contraindicated product administered 19.28 12.29 29 40177 134583 70753655
Impaired healing 19.28 12.29 9 40197 74365 70813873
Aphasia 19.14 12.29 61 40145 43188 70845050
International normalised ratio increased 19.09 12.29 11 40195 80715 70807523
Withdrawal syndrome 19.02 12.29 43 40163 24861 70863377
Complement factor C4 decreased 19.01 12.29 7 40199 301 70887937
Xanthelasma 18.89 12.29 6 40200 164 70888074
Hyperreflexia 18.56 12.29 22 40184 7420 70880818
Loss of consciousness 18.39 12.29 151 40055 155565 70732673
Facial pain 18.35 12.29 23 40183 8213 70880025
Visual impairment 18.31 12.29 92 40114 80158 70808080
Dependence 18.20 12.29 13 40193 2287 70885951
Blood pressure systolic increased 18.11 12.29 5 40201 57254 70830984
Epistaxis 17.93 12.29 19 40187 102608 70785630
Diarrhoea 17.79 12.29 325 39881 783016 70105222
Meningitis aseptic 17.72 12.29 20 40186 6399 70881839
Ovarian neoplasm 17.72 12.29 8 40198 583 70887655
Biliary dyskinesia 17.71 12.29 13 40193 2386 70885852
Complement factor C3 decreased 17.71 12.29 7 40199 366 70887872
Blood bilirubin increased 17.57 12.29 6 40200 59895 70828343
Transverse sinus thrombosis 17.33 12.29 8 40198 614 70887624
Application site erosion 17.23 12.29 6 40200 219 70888019
Hyperacusis 17.19 12.29 12 40194 2036 70886202
Sunburn 17.07 12.29 15 40191 3556 70884682
Peripheral coldness 17.07 12.29 30 40176 14470 70873768
Burns third degree 17.00 12.29 7 40199 407 70887831
Injection site erythema 16.92 12.29 84 40122 72840 70815398
Therapeutic product effect incomplete 16.80 12.29 121 40085 119761 70768477
Teratogenicity 16.78 12.29 6 40200 237 70888001
Multiple sclerosis relapse 16.66 12.29 58 40148 42959 70845279
Lactic acidosis 16.65 12.29 8 40198 65016 70823222
Body temperature increased 16.56 12.29 55 40151 39779 70848459
Superior sagittal sinus thrombosis 16.42 12.29 9 40197 995 70887243
Hepatic enzyme increased 16.25 12.29 41 40165 156949 70731289
Hormone level abnormal 16.23 12.29 11 40195 1779 70886459
Injection site laceration 16.12 12.29 5 40201 126 70888112
Eyelid ptosis 16.12 12.29 24 40182 10078 70878160
Bone marrow failure 16.04 12.29 4 40202 49006 70839232
Toxicity to various agents 16.03 12.29 139 40067 382033 70506205
Haematuria 16.01 12.29 8 40198 63565 70824673
Vertigo 15.86 12.29 74 40132 62569 70825669
Oxygen saturation decreased 15.80 12.29 26 40180 116403 70771835
Meningoradiculitis 15.42 12.29 5 40201 146 70888092
Pancreatic failure 15.35 12.29 10 40196 1514 70886724
Gallbladder injury 15.26 12.29 9 40197 1143 70887095
Swollen tongue 15.26 12.29 51 40155 36995 70851243
Post viral fatigue syndrome 15.19 12.29 6 40200 313 70887925
Joint swelling 15.12 12.29 83 40123 253128 70635110
Tinnitus 15.08 12.29 50 40156 36126 70852112
Large intestinal ulcer haemorrhage 15.07 12.29 6 40200 320 70887918
Cerebral venous sinus thrombosis 14.98 12.29 11 40195 2020 70886218
Gastrointestinal tract irritation 14.97 12.29 7 40199 553 70887685
Aspartate aminotransferase increased 14.89 12.29 31 40175 126947 70761291
Hypoglycaemia 14.84 12.29 19 40187 94345 70793893
Swelling face 14.83 12.29 73 40133 63091 70825147
Torsade de pointes 14.65 12.29 32 40174 18084 70870154
Pericardial effusion 14.49 12.29 3 40203 41773 70846465
Deep vein thrombosis 14.38 12.29 110 40096 110932 70777306
Incorrect disposal of product 14.31 12.29 8 40198 919 70887319
Cardio-respiratory arrest 14.11 12.29 22 40184 100655 70787583
Haemorrhage 14.11 12.29 16 40190 83799 70804439
Peripheral nerve injury 13.75 12.29 7 40199 666 70887572
Stomatitis 13.74 12.29 33 40173 128478 70759760
Injection site urticaria 13.60 12.29 24 40182 11614 70876624
Incorrect product administration duration 13.53 12.29 23 40183 10801 70877437
Injection site injury 13.50 12.29 7 40199 692 70887546
Device difficult to use 13.49 12.29 23 40183 10826 70877412
Cytomegalovirus infection 13.49 12.29 3 40203 39755 70848483
Panic attack 13.47 12.29 35 40171 22084 70866154
Bradycardia 13.32 12.29 32 40174 124583 70763655
Inflammation 13.26 12.29 15 40191 78650 70809588
Drug effect less than expected 13.17 12.29 8 40198 1072 70887166
Major depression 13.16 12.29 20 40186 8554 70879684
Product dispensing error 13.05 12.29 24 40182 11984 70876254
Neutrophil count decreased 12.96 12.29 17 40189 83539 70804699
Choking sensation 12.95 12.29 13 40193 3642 70884596
Lichen planus 12.83 12.29 11 40195 2524 70885714
Somnolence 12.74 12.29 182 40024 215424 70672814
Alanine aminotransferase increased 12.71 12.29 42 40164 147438 70740800
Trismus 12.61 12.29 15 40191 5076 70883162
Neoplasm progression 12.47 12.29 5 40201 45223 70843015
Product use issue 12.45 12.29 56 40150 179881 70708357
Hyperglycaemia 12.43 12.29 11 40195 64661 70823577
Depressive symptom 12.40 12.29 15 40191 5166 70883072
Capillaritis 12.39 12.29 5 40201 276 70887962
Eye pain 12.36 12.29 45 40161 34057 70854181

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC N02CC01 NERVOUS SYSTEM
ANALGESICS
ANTIMIGRAINE PREPARATIONS
Selective serotonin (5HT1) agonists
CHEBI has role CHEBI:35941 serotonin agonists
FDA MoA N0000175763 Serotonin 1b Receptor Agonists
FDA MoA N0000175764 Serotonin 1d Receptor Agonists
FDA EPC N0000175765 Serotonin-1b and Serotonin-1d Receptor Agonist
MeSH PA D002317 Cardiovascular Agents
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D058825 Serotonin 5-HT1 Receptor Agonists
MeSH PA D018490 Serotonin Agents
MeSH PA D017366 Serotonin Receptor Agonists
MeSH PA D014662 Vasoconstrictor Agents

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Migraine indication 37796009 DOID:6364
Cluster headache syndrome indication 193031009
Tachyarrhythmia contraindication 6285003
Alcoholism contraindication 7200002
Hypercholesterolemia contraindication 13644009
Myocardial infarction contraindication 22298006 DOID:5844
Hypertensive disorder contraindication 38341003 DOID:10763
Gastrointestinal ulcer contraindication 40845000
Body fluid retention contraindication 43498006
Chronic heart failure contraindication 48447003
Disorder of cardiovascular system contraindication 49601007 DOID:1287
Hemiplegic migraine contraindication 59292006
Hepatic failure contraindication 59927004
Blood coagulation disorder contraindication 64779008 DOID:1247
Diabetes mellitus contraindication 73211009 DOID:9351
Gastrointestinal hemorrhage contraindication 74474003
Vascular insufficiency of intestine contraindication 82196007
Epilepsy contraindication 84757009 DOID:1826
Prinzmetal angina contraindication 87343002
Kidney disease contraindication 90708001 DOID:557
Liver function tests abnormal contraindication 166603001
Angina pectoris contraindication 194828000
Cerebrovascular accident contraindication 230690007
Coronary artery bypass graft contraindication 232717009
Disease of liver contraindication 235856003 DOID:409
Transient ischemic attack contraindication 266257000 DOID:224
Esophageal dysmotility contraindication 266434009 DOID:9192
Edema contraindication 267038008
Anemia contraindication 271737000 DOID:2355
Cerebral ischemia contraindication 287731003
Pregnancy, function contraindication 289908002
Thromboembolic disorder contraindication 371039008
Serotonin syndrome contraindication 371089000
Cardiovascular event risk contraindication 395112001
Peripheral vascular disease contraindication 400047006
Disorder of coronary artery contraindication 414024009
Myocardial ischemia contraindication 414795007 DOID:3393
Obesity contraindication 414916001 DOID:9970
Hypertensive urgency contraindication 443482000
Smokes tobacco daily contraindication 449868002




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 11.23 acidic
pKa2 13.42 acidic
pKa3 8.28 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
EQ 11MG BASE ONZETRA XSAIL CURRAX N206099 Jan. 27, 2016 RX POWDER NASAL 8327844 Oct. 3, 2023 METHOD OF DRUG DELIVERY VIA THE NASAL CAVITY
EQ 11MG BASE ONZETRA XSAIL CURRAX N206099 Jan. 27, 2016 RX POWDER NASAL 7975690 Aug. 18, 2025 METHOD OF DRUG DELIVERY VIA THE NASAL CAVITY
EQ 11MG BASE ONZETRA XSAIL CURRAX N206099 Jan. 27, 2016 RX POWDER NASAL 8590530 Sept. 15, 2025 METHOD OF DRUG DELIVERY VIA THE NASAL CAVITY
500MG;EQ 85MG BASE TREXIMET CURRAX N021926 April 15, 2008 RX TABLET ORAL 7332183 Oct. 2, 2025 TREATMENT OF MIGRAINE
60MG;EQ 10MG BASE TREXIMET CURRAX N021926 May 14, 2015 DISCN TABLET ORAL 7332183 Oct. 2, 2025 ACUTE TREATMENT OF MIGRAINE
10MG/SPRAY TOSYMRA UPSHER SMITH LABS N210884 Jan. 25, 2019 RX SPRAY NASAL 8440631 May 9, 2026 ACUTE TREATMENT OF MIGRAINE
EQ 11MG BASE ONZETRA XSAIL CURRAX N206099 Jan. 27, 2016 RX POWDER NASAL 10124132 March 6, 2027 ACUTE TREATMENT OF MIGRAINE
EQ 11MG BASE ONZETRA XSAIL CURRAX N206099 Jan. 27, 2016 RX POWDER NASAL 10124132 March 6, 2027 ACUTE TREATMENT OF MIGRAINE BY DELIVERING A POWDERED SUBSTANCE COMPRISING SUMATRIPTAN VIA A BREATH-POWERED DELIVERY DEVICE
EQ 11MG BASE ONZETRA XSAIL CURRAX N206099 Jan. 27, 2016 RX POWDER NASAL 10124132 March 6, 2027 TREATMENT OF MIGRAINE VIA DELIVERY OF SUMATRIPTAN VIA THE NASAL CAVITY
EQ 6.5MG BASE/4HR ZECUITY TEVA BRANDED PHARM N202278 Jan. 17, 2013 DISCN SYSTEM IONTOPHORESIS 7973058 April 12, 2027 METHOD FOR TREATING ACUTE MIGRAINE IN ADULTS, WITH OR WITHOUT AURA, COMPRISING IONTOPHORETIC TRANSDERMAL DELIVERY OF SUMATRIPTAN OR A SALT THEREOF
EQ 6.5MG BASE/4HR ZECUITY TEVA BRANDED PHARM N202278 Jan. 17, 2013 DISCN SYSTEM IONTOPHORESIS 8155737 April 12, 2027 METHOD FOR TREATING ACUTE MIGRAINE IN ADULTS, WITH OR WITHOUT AURA, COMPRISING IONTOPHORETIC TRANSDERMAL DELIVERY OF SUMATRIPTAN OR A SALT THEREOF
EQ 6.5MG BASE/4HR ZECUITY TEVA BRANDED PHARM N202278 Jan. 17, 2013 DISCN SYSTEM IONTOPHORESIS 8470853 April 12, 2027 METHOD FOR TREATING ACUTE MIGRAINE IN ADULTS, WITH OR WITHOUT AURA, COMPRISING IONTOPHORETIC TRANSDERMAL DELIVERY OF SUMATRIPTAN OR A SALT THEREOF
EQ 6.5MG BASE/4HR ZECUITY TEVA BRANDED PHARM N202278 Jan. 17, 2013 DISCN SYSTEM IONTOPHORESIS 9427578 April 12, 2027 METHOD FOR TREATING ACUTE MIGRAINE IN ADULTS, WITH OR WITHOUT AURA, COMPRISING IONTOPHORETIC TRANSDERMAL DELIVERY OF SUMATRIPTAN OR A SALT THEREOF
EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) ALSUMA MERIDIAN MEDCL N022377 June 29, 2010 DISCN INJECTABLE SUBCUTANEOUS 7811254 Aug. 26, 2027 ACUTE TREATMENT OF MIGRAINE ATTACKS, WITH OR WITHOUT AURA, AND THE TREATMENT OF CLUSTER HEADACHE EPISODES
EQ 11MG BASE ONZETRA XSAIL CURRAX N206099 Jan. 27, 2016 RX POWDER NASAL 8875704 April 7, 2028 METHOD OF DRUG DELIVERY VIA THE NASAL CAVITY
EQ 6.5MG BASE/4HR ZECUITY TEVA BRANDED PHARM N202278 Jan. 17, 2013 DISCN SYSTEM IONTOPHORESIS 8366600 April 21, 2029 METHOD FOR TREATING ACUTE MIGRAINE IN ADULTS, WITH OR WITHOUT AURA, COMPRISING IONTOPHORETIC TRANSDERMAL DELIVERY OF SUMATRIPTAN OR A SALT THEREOF, USING A FLOWABLE HYDROGEL FORMULATION
EQ 11MG BASE ONZETRA XSAIL CURRAX N206099 Jan. 27, 2016 RX POWDER NASAL 10076615 July 30, 2029 ACUTE TREATMENT OF MIGRAINE BY DELIVERING A POWDERED SUBSTANCE COMPRISING SUMATRIPTAN VIA A BREATH-POWERED DELIVERY DEVICE
EQ 11MG BASE ONZETRA XSAIL CURRAX N206099 Jan. 27, 2016 RX POWDER NASAL 10076615 July 30, 2029 METHOD OF DELIVERING SUMATRIPTAN TO A NASAL CAVITY
EQ 11MG BASE ONZETRA XSAIL CURRAX N206099 Jan. 27, 2016 RX POWDER NASAL 10076615 July 30, 2029 TREATMENT OF MIGRAINE VIA DELIVERY OF SUMATRIPTAN VIA THE NASAL CAVITY
10MG/SPRAY TOSYMRA UPSHER SMITH LABS N210884 Jan. 25, 2019 RX SPRAY NASAL 10603305 June 16, 2030 ACUTE TREATMENT OF MIGRAINE
10MG/SPRAY TOSYMRA UPSHER SMITH LABS N210884 Jan. 25, 2019 RX SPRAY NASAL 11337962 June 16, 2030 ACUTE TREATMENT OF MIGRAINE
10MG/SPRAY TOSYMRA UPSHER SMITH LABS N210884 Jan. 25, 2019 RX SPRAY NASAL 9610280 June 16, 2030 ACUTE TREATMENT OF MIGRAINE
10MG/SPRAY TOSYMRA UPSHER SMITH LABS N210884 Jan. 25, 2019 RX SPRAY NASAL 9974770 June 16, 2030 ACUTE TREATMENT OF MIGRAINE
EQ 11MG BASE ONZETRA XSAIL CURRAX N206099 Jan. 27, 2016 RX POWDER NASAL 9649456 Oct. 21, 2030 ACUTE TREATMENT OF MIGRAINE
EQ 11MG BASE ONZETRA XSAIL CURRAX N206099 Jan. 27, 2016 RX POWDER NASAL 9649456 Oct. 21, 2030 ACUTE TREATMENT OF MIGRAINE BY DELIVERING A POWDERED SUBSTANCE COMPRISING SUMATRIPTAN VIA A BREATH-POWERED DELIVERY DEVICE
EQ 11MG BASE ONZETRA XSAIL CURRAX N206099 Jan. 27, 2016 RX POWDER NASAL 9649456 Oct. 21, 2030 TREATMENT OF MIGRAINE VIA DELIVERY OF SUMATRIPTAN VIA THE NASAL CAVITY
EQ 6.5MG BASE/4HR ZECUITY TEVA BRANDED PHARM N202278 Jan. 17, 2013 DISCN SYSTEM IONTOPHORESIS 8983594 Nov. 19, 2030 METHOD FOR TREATING ACUTE MIGRAINE IN ADULTS, WITH OR WITHOUT AURA, COMPRISING IONTOPHORETIC TRANSDERMAL DELIVERY OF SUMATRIPTAN OR A SALT THEREOF
10MG/SPRAY TOSYMRA UPSHER SMITH LABS N210884 Jan. 25, 2019 RX SPRAY NASAL 9211282 July 19, 2031 ACUTE TREATMENT OF MIGRAINE
EQ 6.5MG BASE/4HR ZECUITY TEVA BRANDED PHARM N202278 Jan. 17, 2013 DISCN SYSTEM IONTOPHORESIS 9327114 Oct. 8, 2032 METHOD FOR TREATING ACUTE MIGRAINE IN ADULTS, WITH OR WITHOUT AURA, COMPRISING IONTOPHORETIC TRANSDERMAL DELIVERY OF SUMATRIPTAN OR A SALT THEREOF
EQ 11MG BASE ONZETRA XSAIL CURRAX N206099 Jan. 27, 2016 RX POWDER NASAL 10478574 Nov. 4, 2033 METHOD OF DELIVERING SUMATRIPTAN TO A NASAL CAVITY
EQ 3MG BASE/0.5ML (EQ 3MG BASE/0.5ML) ZEMBRACE SYMTOUCH UPSHER SMITH LABS N208223 Jan. 28, 2016 RX SOLUTION SUBCUTANEOUS 10537554 Jan. 29, 2036 TREATMENT OF MIGRAINE
EQ 3MG BASE/0.5ML (EQ 3MG BASE/0.5ML) ZEMBRACE SYMTOUCH UPSHER SMITH LABS N208223 Jan. 28, 2016 RX SOLUTION SUBCUTANEOUS 11364224 Jan. 29, 2036 TREATMENT OF MIGRAINE

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
5-hydroxytryptamine receptor 1D GPCR AGONIST Ki 8.92 CHEMBL CHEMBL
5-hydroxytryptamine receptor 1B GPCR AGONIST Ki 8.26 CHEMBL CHEMBL
5-hydroxytryptamine receptor 2C GPCR IC50 8.14 CHEMBL
5-hydroxytryptamine receptor 6 GPCR ANTAGONIST Ki 5.60 IUPHAR
5-hydroxytryptamine receptor 7 GPCR ANTAGONIST Ki 6 IUPHAR
5-hydroxytryptamine receptor 3A Ion channel IC50 8.03 CHEMBL
5-hydroxytryptamine receptor 5A GPCR IC50 6.30 CHEMBL
5-hydroxytryptamine receptor 1F GPCR Ki 7.59 CHEMBL
5-hydroxytryptamine receptor 1E GPCR IC50 5.26 CHEMBL
Multidrug and toxin extrusion protein 1 Transporter IC50 5.17 CHEMBL
5-hydroxytryptamine receptor 1A GPCR Ki 6.64 CHEMBL
5-hydroxytryptamine receptor 2A GPCR Ki 6.42 CHEMBL
5-hydroxytryptamine receptor 1B GPCR Ki 7.64 CHEMBL
5-hydroxytryptamine receptor 1A GPCR IC50 6.19 CHEMBL
5-hydroxytryptamine receptor 7 GPCR ANTAGONIST Ki 6.60 IUPHAR
5-hydroxytryptamine receptor 1D GPCR IC50 7.70 CHEMBL
5-hydroxytryptamine receptor 1A GPCR IC50 6.35 CHEMBL
5-hydroxytryptamine receptor 1D GPCR IC50 7.21 CHEMBL
5-hydroxytryptamine receptor 6 GPCR ANTAGONIST Ki 5.20 IUPHAR
5-hydroxytryptamine receptor 1B GPCR Ki 8.19 CHEMBL
5-hydroxytryptamine 1D receptor Unclassified IC50 7.23 CHEMBL
5-hydroxytryptamine receptor 5A GPCR AGONIST Ki 4.80 IUPHAR

External reference:

IDSource
4021050 VUID
N0000148514 NUI
D00451 KEGG_DRUG
103628-48-4 SECONDARY_CAS_RN
4020790 VANDF
4021050 VANDF
C0075632 UMLSCUI
CHEBI:10650 CHEBI
CHEMBL128 ChEMBL_ID
DB00669 DRUGBANK_ID
CHEMBL1201150 ChEMBL_ID
D018170 MESH_DESCRIPTOR_UI
5358 PUBCHEM_CID
54 IUPHAR_LIGAND_ID
6125 INN_ID
8R78F6L9VO UNII
37418 RXNORM
158892 MMSL
166806 MMSL
25268 MMSL
31925 MMSL
5536 MMSL
d03160 MMSL
004044 NDDF
004045 NDDF
322822007 SNOMEDCT_US
395892000 SNOMEDCT_US
96215002 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Sumatriptan HUMAN PRESCRIPTION DRUG LABEL 1 0093-2013 INJECTION 4 mg SUBCUTANEOUS ANDA 28 sections
Sumatriptan HUMAN PRESCRIPTION DRUG LABEL 1 0093-2014 INJECTION 6 mg SUBCUTANEOUS ANDA 28 sections
SUMATRIPTAN HUMAN PRESCRIPTION DRUG LABEL 1 0143-9638 INJECTION 6 mg SUBCUTANEOUS ANDA 27 sections
IMITREX HUMAN PRESCRIPTION DRUG LABEL 1 0173-0478 INJECTION 6 mg SUBCUTANEOUS NDA 28 sections
IMITREX HUMAN PRESCRIPTION DRUG LABEL 1 0173-0478 INJECTION 6 mg SUBCUTANEOUS NDA 28 sections
IMITREX HUMAN PRESCRIPTION DRUG LABEL 1 0173-0479 INJECTION 6 mg SUBCUTANEOUS NDA 28 sections
IMITREX HUMAN PRESCRIPTION DRUG LABEL 1 0173-0479 INJECTION 6 mg SUBCUTANEOUS NDA 28 sections
IMITREX HUMAN PRESCRIPTION DRUG LABEL 1 0173-0523 SPRAY 20 mg NASAL NDA 27 sections
IMITREX HUMAN PRESCRIPTION DRUG LABEL 1 0173-0523 SPRAY 20 mg NASAL NDA 27 sections
IMITREX HUMAN PRESCRIPTION DRUG LABEL 1 0173-0524 SPRAY 5 mg NASAL NDA 27 sections
IMITREX HUMAN PRESCRIPTION DRUG LABEL 1 0173-0524 SPRAY 5 mg NASAL NDA 27 sections
IMITREX HUMAN PRESCRIPTION DRUG LABEL 1 0173-0735 TABLET, FILM COATED 25 mg ORAL NDA 27 sections
IMITREX HUMAN PRESCRIPTION DRUG LABEL 1 0173-0735 TABLET, FILM COATED 25 mg ORAL NDA 27 sections
IMITREX HUMAN PRESCRIPTION DRUG LABEL 1 0173-0736 TABLET, FILM COATED 50 mg ORAL NDA 27 sections
IMITREX HUMAN PRESCRIPTION DRUG LABEL 1 0173-0736 TABLET, FILM COATED 50 mg ORAL NDA 27 sections
IMITREX HUMAN PRESCRIPTION DRUG LABEL 1 0173-0737 TABLET, FILM COATED 100 mg ORAL NDA 27 sections
IMITREX HUMAN PRESCRIPTION DRUG LABEL 1 0173-0737 TABLET, FILM COATED 100 mg ORAL NDA 27 sections
IMITREX HUMAN PRESCRIPTION DRUG LABEL 1 0173-0739 INJECTION 4 mg SUBCUTANEOUS NDA 28 sections
IMITREX HUMAN PRESCRIPTION DRUG LABEL 1 0173-0739 INJECTION 4 mg SUBCUTANEOUS NDA 28 sections
ZEMBRACE SYMTOUCH HUMAN PRESCRIPTION DRUG LABEL 1 0245-0809 INJECTION, SOLUTION 3 mg SUBCUTANEOUS NDA 31 sections
TOSYMRA HUMAN PRESCRIPTION DRUG LABEL 1 0245-0812 SPRAY 10 mg NASAL NDA 31 sections
Sumatriptan Succinate HUMAN PRESCRIPTION DRUG LABEL 1 0378-5630 TABLET, FILM COATED 25 mg ORAL ANDA 28 sections
Sumatriptan Succinate HUMAN PRESCRIPTION DRUG LABEL 1 0378-5630 TABLET, FILM COATED 25 mg ORAL ANDA 28 sections
Sumatriptan Succinate HUMAN PRESCRIPTION DRUG LABEL 1 0378-5631 TABLET, FILM COATED 50 mg ORAL ANDA 28 sections
Sumatriptan Succinate HUMAN PRESCRIPTION DRUG LABEL 1 0378-5631 TABLET, FILM COATED 50 mg ORAL ANDA 28 sections
Sumatriptan Succinate HUMAN PRESCRIPTION DRUG LABEL 1 0378-5632 TABLET, FILM COATED 100 mg ORAL ANDA 28 sections
Sumatriptan Succinate HUMAN PRESCRIPTION DRUG LABEL 1 0378-5632 TABLET, FILM COATED 100 mg ORAL ANDA 28 sections
Sumatriptan HUMAN PRESCRIPTION DRUG LABEL 1 0527-1818 SPRAY 5 mg NASAL ANDA 28 sections
Sumatriptan HUMAN PRESCRIPTION DRUG LABEL 1 0527-1859 SPRAY 20 mg NASAL ANDA 28 sections
Sumatriptan Succinate HUMAN PRESCRIPTION DRUG LABEL 1 16590-300 TABLET, FILM COATED 100 mg ORAL NDA 13 sections